American Epilepsy Society (AES): Written Comments to Norman E. “Ned” Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA)

Thursday, October 24, 2019

The AES believes that these compounds need to be under the full regulatory control of the FDA and that distribution should be limited to the well-developed legend drug process. While drug regulation is desired, in the interim, the following equally important steps should be taken to assure continuous and safe access to CBD products for patients who are currently benefiting from them.